Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion

Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME followi...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 11; no. 1; pp. 8303 - 7
Main Authors Wecker, Thomas, Grundel, Bastian, Grundel, Milena, Bründer, Marie-Christine, Trick, Simon, Lange, Clemens, Böhringer, Daniel, Agostini, Hansjürgen, Stahl, Andreas
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 15.04.2021
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group.
AbstractList Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group.
Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group.
Abstract Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group.
Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group.Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group.
ArticleNumber 8303
Author Stahl, Andreas
Böhringer, Daniel
Agostini, Hansjürgen
Wecker, Thomas
Grundel, Bastian
Trick, Simon
Lange, Clemens
Grundel, Milena
Bründer, Marie-Christine
Author_xml – sequence: 1
  givenname: Thomas
  surname: Wecker
  fullname: Wecker, Thomas
  email: tw@augenarzt-wecker.de
  organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Ophthalmic Practice Dr. Wecker
– sequence: 2
  givenname: Bastian
  surname: Grundel
  fullname: Grundel, Bastian
  organization: Department of Ophthalmology, University Medical Center
– sequence: 3
  givenname: Milena
  surname: Grundel
  fullname: Grundel, Milena
  organization: Department of Ophthalmology, University Medical Center
– sequence: 4
  givenname: Marie-Christine
  surname: Bründer
  fullname: Bründer, Marie-Christine
  organization: Department of Ophthalmology, University Medical Center
– sequence: 5
  givenname: Simon
  surname: Trick
  fullname: Trick, Simon
  organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Department of Ophthalmology, University Medical Center
– sequence: 6
  givenname: Clemens
  surname: Lange
  fullname: Lange, Clemens
  organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg
– sequence: 7
  givenname: Daniel
  surname: Böhringer
  fullname: Böhringer, Daniel
  organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg
– sequence: 8
  givenname: Hansjürgen
  surname: Agostini
  fullname: Agostini, Hansjürgen
  organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg
– sequence: 9
  givenname: Andreas
  surname: Stahl
  fullname: Stahl, Andreas
  organization: Department of Ophthalmology, University Medical Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33859243$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhS1UREvpH2CBIrFhE_AjiZ0NEqp4VKqEhGBtOfbN1CMnHmxngH_P7aSUtotm49j-zvHx9X1OjuY4AyEvGX3LqFDvcsPaXtWUs1rJppN194SccNq0NRecH935PyZnOW8pfi3vG9Y_I8dCqLbnjTgh8A1MqIMfoZrA-WWqCqSpGmMI8Ve97CpnisFpqvxcktn7klBQOfhtJihXJmOqyk-7YOaCSJWg-BmBPeAkWhuW7OP8gjwdTchwdjOekh-fPn4__1Jffv18cf7hsrZtQ0stLbNODrSXo2IDc0Z0Q9u5VqqBWSExvGXSUeikbCXngtpBAO34OAjnBurEKblYfV00W71LfjLpj47G68NCTBttUvE2gDYdU0rS0SkmG676wQAfBNrJkVEKHL3er167ZcDSWLi-f7hnen9n9ld6E_da0ZZy2aPBmxuDFH8ukIuefLYQsFQQl6x5y5qONlQ2iL5-gG7jkrCOB0rQnqMlUq_uJrqN8u81EeArYFPMOcF4izCqr7tGr12jsWv0oWt0hyL1QGR9MQVfDW_lw-NSsUoznjNvIP2P_YjqL3fY1rE
CitedBy_id crossref_primary_10_1016_j_bj_2023_100607
crossref_primary_10_1136_bmjophth_2024_001722
crossref_primary_10_3389_fmed_2024_1454591
crossref_primary_10_3389_fphar_2022_1029584
crossref_primary_10_7759_cureus_80391
crossref_primary_10_12677_ACM_2023_1371619
crossref_primary_10_1007_s00417_021_05369_9
Cites_doi 10.1159/000494224
10.18637/jss.v040.i01
10.1007/s00417-016-3431-x
10.1001/archopht.124.5.726
10.1155/2020/6830148
10.1155/2017/5831682
10.1159/000442258
10.18637/jss.v021.i12
10.1080/15569527.2019.1614020
10.1016/j.ophtha.2011.05.014
10.1016/j.jcjo.2018.12.005
10.1016/j.ophtha.2010.03.032
10.1007/s00417-018-4016-7
10.1007/s00417-008-0926-0
10.1016/j.exer.2019.01.006
10.1007/s00347-012-2737-2
10.1016/j.ophtha.2009.07.017
10.1159/000473864
10.1016/j.ophtha.2010.01.060
10.1167/iovs.05-0981
10.4103/ijo.IJO_382_19
10.1007/s00417-017-3852-1
10.1038/s41598-019-38934-8
10.4103/ijo.IJO_1905_18
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-021-87467-6
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central (New)
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
Publicly Available Content Database


MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 7
ExternalDocumentID oai_doaj_org_article_a618870fd8174289bae2b33e07f100e2
PMC8050279
33859243
10_1038_s41598_021_87467_6
Genre Journal Article
GrantInformation_xml – fundername: Albert-Ludwigs-Universität Freiburg im Breisgau (1016)
– fundername: ;
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
NPM
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
Q9U
7X8
AARCD
5PM
PUEGO
ID FETCH-LOGICAL-c540t-7c1cd7b097f81b1da36b56d578b1c37941c17d0e677572230cb3e062fb3ddb0d3
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:13:40 EDT 2025
Thu Aug 21 13:57:21 EDT 2025
Tue Aug 05 09:24:47 EDT 2025
Fri Jul 25 10:03:43 EDT 2025
Thu Apr 03 07:08:28 EDT 2025
Thu Apr 24 23:03:59 EDT 2025
Tue Jul 01 01:07:57 EDT 2025
Fri Feb 21 02:39:09 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-7c1cd7b097f81b1da36b56d578b1c37941c17d0e677572230cb3e062fb3ddb0d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-021-87467-6
PMID 33859243
PQID 2513092502
PQPubID 2041939
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_a618870fd8174289bae2b33e07f100e2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8050279
proquest_miscellaneous_2514604074
proquest_journals_2513092502
pubmed_primary_33859243
crossref_primary_10_1038_s41598_021_87467_6
crossref_citationtrail_10_1038_s41598_021_87467_6
springer_journals_10_1038_s41598_021_87467_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-04-15
PublicationDateYYYYMMDD 2021-04-15
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-04-15
  day: 15
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Lange, Feltgen, Junker, Schulze-Bonsel, Bach (CR8) 2009; 247
Schulze-Bonsel, Feltgen, Burau, Hansen, Bach (CR9) 2006; 47
Nicula, Nicula, Rednik, Bulboaca, Crișan (CR23) 2020; 2020
McIntosh (CR4) 2010; 117
Pielen (CR13) 2017; 2017
Wickham (CR11) 2011; 40
Schmitz (CR20) 2014; 111
Haller (CR19) 2011; 118
Winterhalter (CR16) 2018; 256
Haller (CR18) 2010; 117
Hanhart, Rozenman (CR17) 2017; 238
Li (CR2) 2019; 241
Cugati, Wang, Rochtchina, Mitchell (CR3) 2006; 124
Wickham (CR12) 2007; 21
Teja, Sawatzky, Wiens, Maberley, Ma (CR22) 2019; 54
Hu (CR5) 2019; 67
Georgalas (CR21) 2019; 38
Rogers (CR1) 2010; 117
Walz (CR6) 2019; 181
Eter (CR14) 2017; 255
Chiquet (CR15) 2016; 55
(CR10) 2014
Wecker (CR7) 2019; 9
Blanc (CR24) 2018; 256
S Rogers (87467_CR1) 2010; 117
N Eter (87467_CR14) 2017; 255
H Wickham (87467_CR11) 2011; 40
S Winterhalter (87467_CR16) 2018; 256
J Blanc (87467_CR24) 2018; 256
JA Haller (87467_CR19) 2011; 118
S Cugati (87467_CR3) 2006; 124
RL McIntosh (87467_CR4) 2010; 117
JM Walz (87467_CR6) 2019; 181
C Nicula (87467_CR23) 2020; 2020
J Hanhart (87467_CR17) 2017; 238
K Schulze-Bonsel (87467_CR9) 2006; 47
L Georgalas (87467_CR21) 2019; 38
C Chiquet (87467_CR15) 2016; 55
JA Haller (87467_CR18) 2010; 117
K Schmitz (87467_CR20) 2014; 111
JQ Li (87467_CR2) 2019; 241
S Teja (87467_CR22) 2019; 54
C Lange (87467_CR8) 2009; 247
T Wecker (87467_CR7) 2019; 9
Q Hu (87467_CR5) 2019; 67
R Core Team (87467_CR10) 2014
H Wickham (87467_CR12) 2007; 21
A Pielen (87467_CR13) 2017; 2017
References_xml – volume: 241
  start-page: 183
  year: 2019
  end-page: 189
  ident: CR2
  article-title: Prevalence of retinal vein occlusion in Europe: A systematic review and meta-analysis
  publication-title: Ophthalmologica
  doi: 10.1159/000494224
– volume: 40
  start-page: 1
  year: 2011
  end-page: 29
  ident: CR11
  article-title: The split-apply-combine strategy for data analysis
  publication-title: J. Stat. Softw.
  doi: 10.18637/jss.v040.i01
– volume: 255
  start-page: 77
  year: 2017
  end-page: 87
  ident: CR14
  article-title: Dexamethasone intravitreal implant in retinal vein occlusion: Real-life data from a prospective, multicenter clinical trial
  publication-title: Graefes Arch. Clin. Exp. Ophthalmol.
  doi: 10.1007/s00417-016-3431-x
– volume: 124
  start-page: 726
  year: 2006
  end-page: 732
  ident: CR3
  article-title: Ten-year incidence of retinal vein occlusion in an older population: The Blue Mountains Eye Study
  publication-title: Arch. Ophthalmol.
  doi: 10.1001/archopht.124.5.726
– volume: 2020
  start-page: 6830148
  year: 2020
  ident: CR23
  article-title: Morphological and functional outcomes after intravitreal dexamethasone injection for macular edema in patients with central vein occlusion at 48-week follow-up
  publication-title: J. Ophthalmol.
  doi: 10.1155/2020/6830148
– volume: 2017
  start-page: 5831682
  year: 2017
  ident: CR13
  article-title: Switch of intravitreal therapy for macular edema secondary to retinal vein Occlusion from anti-VEGF to dexamethasone implant and vice versa
  publication-title: J. Ophthalmol.
  doi: 10.1155/2017/5831682
– volume: 55
  start-page: 152
  year: 2016
  end-page: 158
  ident: CR15
  article-title: Retinal vein occlusions: Therapeutic switch in macular oedema treatment with a 12-month follow-up
  publication-title: Ophthalm. Res.
  doi: 10.1159/000442258
– volume: 21
  start-page: 1
  year: 2007
  end-page: 20
  ident: CR12
  article-title: Reshaping data with the reshape package
  publication-title: J. Stat. Softw.
  doi: 10.18637/jss.v021.i12
– volume: 38
  start-page: 330
  year: 2019
  end-page: 337
  ident: CR21
  article-title: Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: A 12-month prospective study
  publication-title: Cutan. Ocul. Toxicol.
  doi: 10.1080/15569527.2019.1614020
– volume: 118
  start-page: 2453
  year: 2011
  end-page: 2460
  ident: CR19
  article-title: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2011.05.014
– volume: 54
  start-page: 540
  year: 2019
  end-page: 547
  ident: CR22
  article-title: Ozurdex for refractory macular edema secondary to diabetes, vein occlusion, uveitis and pseudophakia
  publication-title: Can. J. Ophthalmol.
  doi: 10.1016/j.jcjo.2018.12.005
– volume: 117
  start-page: 1134
  year: 2010
  end-page: 1146.e3
  ident: CR18
  article-title: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2010.03.032
– volume: 256
  start-page: 1441
  year: 2018
  end-page: 1448
  ident: CR24
  article-title: Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: A 3-year experience
  publication-title: Graefes. Arch. Clin. Exp. Ophthalmol.
  doi: 10.1007/s00417-018-4016-7
– volume: 247
  start-page: 137
  year: 2009
  end-page: 142
  ident: CR8
  article-title: Resolving the clinical acuity categories ‘hand motion’ and ‘counting fingers’ using the Freiburg Visual Acuity Test (FrACT)
  publication-title: Graefes Arch. Clin. Exp. Ophthalmol.
  doi: 10.1007/s00417-008-0926-0
– volume: 181
  start-page: 98
  year: 2019
  end-page: 104
  ident: CR6
  article-title: Impact of angiogenic activation and inhibition on miRNA profiles of human retinal endothelial cells
  publication-title: Exp. Eye Res.
  doi: 10.1016/j.exer.2019.01.006
– volume: 111
  start-page: 44
  year: 2014
  end-page: 52
  ident: CR20
  article-title: Reliability and safety of intravitreal Ozurdex injections. The ZERO study
  publication-title: Ophthalmologe
  doi: 10.1007/s00347-012-2737-2
– volume: 117
  start-page: 313
  year: 2010
  end-page: 319.e1
  ident: CR1
  article-title: The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2009.07.017
– volume: 238
  start-page: 110
  year: 2017
  end-page: 118
  ident: CR17
  article-title: Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions
  publication-title: Ophthalmologica
  doi: 10.1159/000473864
– year: 2014
  ident: CR10
  publication-title: R: A Language and Environment for Statistical Computing
– volume: 117
  start-page: 1113
  year: 2010
  end-page: 1123.e15
  ident: CR4
  article-title: Natural history of central retinal vein occlusion: An evidence-based systematic review
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2010.01.060
– volume: 47
  start-page: 1236
  year: 2006
  end-page: 1240
  ident: CR9
  article-title: Visual acuities ‘hand motion’ and ‘counting fingers’ can be quantified with the freiburg visual acuity test
  publication-title: Invest. Ophthalmol. Vis. Sci.
  doi: 10.1167/iovs.05-0981
– volume: 67
  start-page: 1800
  year: 2019
  end-page: 1809
  ident: CR5
  article-title: Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials
  publication-title: Indian J. Ophthalmol.
  doi: 10.4103/ijo.IJO_382_19
– volume: 256
  start-page: 267
  year: 2018
  end-page: 279
  ident: CR16
  article-title: Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months
  publication-title: Graefes Arch. Clin. Exp. Ophthalmol.
  doi: 10.1007/s00417-017-3852-1
– volume: 9
  start-page: 3301
  year: 2019
  ident: CR7
  article-title: Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-38934-8
– volume: 256
  start-page: 1441
  year: 2018
  ident: 87467_CR24
  publication-title: Graefes. Arch. Clin. Exp. Ophthalmol.
  doi: 10.1007/s00417-018-4016-7
– volume: 40
  start-page: 1
  year: 2011
  ident: 87467_CR11
  publication-title: J. Stat. Softw.
– volume: 238
  start-page: 110
  year: 2017
  ident: 87467_CR17
  publication-title: Ophthalmologica
  doi: 10.1159/000473864
– volume: 38
  start-page: 330
  year: 2019
  ident: 87467_CR21
  publication-title: Cutan. Ocul. Toxicol.
  doi: 10.1080/15569527.2019.1614020
– volume: 111
  start-page: 44
  year: 2014
  ident: 87467_CR20
  publication-title: Ophthalmologe
  doi: 10.1007/s00347-012-2737-2
– volume: 117
  start-page: 1134
  year: 2010
  ident: 87467_CR18
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2010.03.032
– volume: 117
  start-page: 313
  year: 2010
  ident: 87467_CR1
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2009.07.017
– volume: 181
  start-page: 98
  year: 2019
  ident: 87467_CR6
  publication-title: Exp. Eye Res.
  doi: 10.1016/j.exer.2019.01.006
– volume: 256
  start-page: 267
  year: 2018
  ident: 87467_CR16
  publication-title: Graefes Arch. Clin. Exp. Ophthalmol.
  doi: 10.1007/s00417-017-3852-1
– volume: 124
  start-page: 726
  year: 2006
  ident: 87467_CR3
  publication-title: Arch. Ophthalmol.
  doi: 10.1001/archopht.124.5.726
– volume: 255
  start-page: 77
  year: 2017
  ident: 87467_CR14
  publication-title: Graefes Arch. Clin. Exp. Ophthalmol.
  doi: 10.1007/s00417-016-3431-x
– volume-title: R: A Language and Environment for Statistical Computing
  year: 2014
  ident: 87467_CR10
– volume: 2017
  start-page: 5831682
  year: 2017
  ident: 87467_CR13
  publication-title: J. Ophthalmol.
  doi: 10.1155/2017/5831682
– volume: 117
  start-page: 1113
  year: 2010
  ident: 87467_CR4
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2010.01.060
– volume: 67
  start-page: 1800
  year: 2019
  ident: 87467_CR5
  publication-title: Indian J. Ophthalmol.
  doi: 10.4103/ijo.IJO_1905_18
– volume: 55
  start-page: 152
  year: 2016
  ident: 87467_CR15
  publication-title: Ophthalm. Res.
  doi: 10.1159/000442258
– volume: 247
  start-page: 137
  year: 2009
  ident: 87467_CR8
  publication-title: Graefes Arch. Clin. Exp. Ophthalmol.
  doi: 10.1007/s00417-008-0926-0
– volume: 47
  start-page: 1236
  year: 2006
  ident: 87467_CR9
  publication-title: Invest. Ophthalmol. Vis. Sci.
  doi: 10.1167/iovs.05-0981
– volume: 118
  start-page: 2453
  year: 2011
  ident: 87467_CR19
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2011.05.014
– volume: 9
  start-page: 3301
  year: 2019
  ident: 87467_CR7
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-38934-8
– volume: 54
  start-page: 540
  year: 2019
  ident: 87467_CR22
  publication-title: Can. J. Ophthalmol.
  doi: 10.1016/j.jcjo.2018.12.005
– volume: 21
  start-page: 1
  year: 2007
  ident: 87467_CR12
  publication-title: J. Stat. Softw.
  doi: 10.18637/jss.v021.i12
– volume: 241
  start-page: 183
  year: 2019
  ident: 87467_CR2
  publication-title: Ophthalmologica
  doi: 10.1159/000494224
– volume: 2020
  start-page: 6830148
  year: 2020
  ident: 87467_CR23
  publication-title: J. Ophthalmol.
SSID ssj0000529419
Score 2.3453329
Snippet Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of...
Abstract Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 8303
SubjectTerms 692/308
692/699/3161/3175
Acuity
Cataracts
Corticoids
Corticosteroids
Dexamethasone
Edema
Electronic medical records
Eye
Humanities and Social Sciences
multidisciplinary
Occlusion
Patients
Retina
Science
Science (multidisciplinary)
Steroids
Surgery
Transplants & implants
Vascular endothelial growth factor
SummonAdditionalLinks – databaseName: Directory of Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhUOilNE0fbtKiQm-tiWTJkn1sS0MINIfSQG5CT2pwdpdknSb_vjOyd5NNX5cebclomJc-eUYzhLwNNkrVRFU2FU-l1DJgkNCWtrGxdjwmn7Pdv5yoo1N5fFaf3Wn1hTlhY3ngkXEHVnGwA5ZCA9gZTgfOxsoJEZlOnLGYvS_seXcOU2NV76qVvJ1uyTDRHFzCToW3ySoODgC9g9rYiXLB_t-hzF-TJe9FTPNGdPiYPJoQJP0wUr5DtuLsCXkw9pS82SXxK0C_su9SpBg3H84pOl-aQN7zH-WwoJgTCo8XtMOVrjpMNe9piNcWu0lbwN-RdueLHlgOUyjecsT1riI8zL3vB_y_9pScHn7-9umonHoplB4w2bLUnvugHWt1AqDKgxXK1SqAvTruBRgl91wHFpXWtQbIwLwDHqsqORGCY0E8I9szIOAFoVXlAfQJIQPAr9gEJ4NMbfDWShSQKAhf8dX4qdA49rvoTQ54i8aMsjAgC5NlYVRB3q2_WYxlNv46-yOKaz0TS2TnF6A4ZlIc8y_FKcj-SthmsttLA2hPsBZgIQy_WQ-DxWEYxc7ifMhzpALfp2VBno-6saYEDvw1nGiBB3pDazZI3RyZdd9zVe-Gwaq6Lcj7lX7dkvVnVrz8H6zYIw8rNAwsYVnvk-3lxRBfAdZautfZrH4CzeYkDQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4t1AQUbiBlHt2LGTEwJEVSHBAVFpb5ZfgUjpZtndFPj3zDjZVMujx2y88sTz-uwZzxDyItgoVRVVXhW8yaWWAYOENreVjaXjsfEp2_3jJ3V6Jj8sysV04LaZ0ip3NjEZ6tB7PCM_Bj8sWA0Ou3i9-p5j1yiMrk4tNK6TG1i6DFO69ELPZywYxZK8nu7KMFEdb8Bf4Z2ygoMZQBuh9vxRKtv_L6z5d8rkH3HT5I5O7pDbE46kb0bG3yXX4vIeuTl2lvx1n8TPAADzrm0ixej5cE7RBNMGuN7_yIcVxcxQeFzTFme6aDHhvKMh_rTYU9oCCo-0PV91sPAwhOJdR5zvIsJD73034CnbA3J28v7Lu9N86qiQe0Bm21x77oN2rNYNwFUerFCuVAG01nEvQDW55zqwqLQuNQAH5p2ITBWNEyE4FsRDcrAEAg4JLQoP0E8IGQCExSo4GWRTB2-thB1NLTLCd-tq_FRuHLtedCaFvUVlRl4Y4IVJvDAqIy_n_6zGYhtXjn6L7JpHYqHs9EO__momvTNWcTCjrAkVbL2ALmdj4QR8lG44Y7HIyNGO2WbS3o25lLWMPJ9fg95hMMUuYz-kMVKBBdQyI49G2ZgpgW1_CftaWAO9JzV7pO6_WbbfUm3visGsus7Iq518XZL1_6V4fPVXPCG3ChR5LFFZHpGD7XqITwFLbd2zpDC_AU2vHCo
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3daxQxEA-1Ivgi9Xu1SgTfdDHZZJPdx3pYiqAPYqFvIV-rC9u743rb1v_emeyHnFbBx2wmZDYzk_ySmUwIeR1slKqKKq8K3uRSy4BOQpvbysbS8dj4FO3-6bM6OZUfz8qzPVJMd2FS0H5KaZmm6Sk67N0FLDR4GazgYL9o3OoWuY2p21GrF2oxn6ug50ryerwfw0R1Q9OdNSil6r8JX_4ZJvmbrzQtQccH5N6IHenRwO19sheXD8id4TXJHw9J_AKgL-_aJlL0mPfnFKdd2oCkV1d5v6YYDQrFDW2xp8sWg8w7GuK1xXekLSDvSNvzdQeDDSQU7zdif5cRCivvux5P1h6R0-MPXxcn-fiKQu4BjW1z7bkP2rFaNwBRebBCuVIFsFTHvQBz5J7rwKLSutQAFph3IjJVNE6E4FgQj8n-Ehh4SmhReIB7QsgAwCtWwckgmzp4ayXsYmqRET6Nq_FjinF86aIzydUtKjPIwoAsTJKFURl5M7dZDwk2_kn9HsU1U2Jy7PRhtflmRmUxVnGYOlkTKthuAV_OxsIJ-CndcMZikZHDSdhmtNgLAzhPsBoAIVS_mqvB1tCBYpdx1ScaqWDW0zIjTwbdmDmBrX4Je1kYA72jNTus7tYs2-8pn3fFoFddZ-TtpF-_2Pr7UDz7P_Ln5G6BJoBpKstDsr_d9PEF4Kmte5kM6Cfwjxos
  priority: 102
  providerName: Springer Nature
Title Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
URI https://link.springer.com/article/10.1038/s41598-021-87467-6
https://www.ncbi.nlm.nih.gov/pubmed/33859243
https://www.proquest.com/docview/2513092502
https://www.proquest.com/docview/2514604074
https://pubmed.ncbi.nlm.nih.gov/PMC8050279
https://doaj.org/article/a618870fd8174289bae2b33e07f100e2
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELf2ISReEN-EjSpIvEEgjh07eUCoqzZNlTahQaW-Rf4KRMra0jX7-O-5c5KiQkHiKUrsxte7-9k_x_YdIW-sclxkTkRZQsuIS25xkVBFKlMu1dSVxu92PzsXpxM-nqbTHdKnO-oUeLV1aof5pCbL-v3tj7tPAPiP7ZHx7MMVDEJ4UCyhgG0Evtgl-zAySQTqWUf321jfSc59rg8Mwh4BmUi6czTbX7MxVvmQ_tt46J_bKX9bU_VD1clD8qDjmOGwdYpHZMfNHpN7bdbJuyfEXQA5jOqqdCGurDeXIXbPYQkeMb-JmkWIu0bhdhlW2NJ1hZvR69C6W4X5phUwdBdWl4sajAJVQjwHie1dO7iZG1M3-AXuKZmcHH8dnUZdtoXIAGtbRdJQY6WOc1kClaVWMaFTYQHRmhoGsKWGShs7IWUqgVTERjMXi6TUzFodW_aM7M1AgBckTBIDtJAxboGgucxqbnmZW6MUh9lOzgJCe70WpgtFjhkx6sIvibOsaG1RgC0Kb4tCBOTt-jeLNhDHP2sfobnWNTGItn8wX34rOkwWSlDoYuPSZjAtA7m0colm8KdkSePYJQE57I1d9I5ZAB9kcQ7EEYpfr4sBk7jQomZu3vg6XEDvKHlAnre-sZaEsSyFOS_oQG54zYaomyWz6ruP-53F0KrMA_Ku969fYv1dFS__S3EH5H6CCMBolukh2VstG_cKaNdKD8iunMoB2R8Ox1_GcD06Pv98AU9HYjTwnzIGHm0_Ae_tKws
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELbKVgheEDeBAkGCJ4gaH7GTB4QotNrSdoWqVuqb6yt0pe3udo-W_il-IzM5tlqOvvUxiRNPPJ_n8NgzhLz1JgiZB5nkjJaJUMJjkNAkJjchszSUrtrtvteT3UPx7Sg7WiG_2rMwuK2ylYmVoPYjh2vk66CHeVqAwmafxmcJVo3C6GpbQqOGxU64vACXbfpx-yvw9x1jW5sHX7pJU1UgcWCdzBLlqPPKpoUqwWSj3nBpM-kBuZY6DvCkjiqfBqlUpkB5ps7ykEpWWu69TT2H794iq4KDK9Mhqxubve_7i1UdjJsJWjSnc1Ker09BQ-IpNkZB8KBUkksasCoU8C_r9u9Nmn9EaisFuHWf3Gss1_hzDbUHZCUMH5LbdS3Ly0ck7IPJmQz6ZYgxXj8_jVHoxyXgbHSRzMcx7kWFy0ncx57O-7jFfRD78NNgFWsDdn-I-6fjAbAamsR4uhL7Ow9wMXJuMMd1vcfk8EZG-wnpDIGAZyRmzIGxybnwYPaF3FvhRVl4Z4wAH6rgEaHtuGrXJDjHOhsDXQXaea5rXmjgha54oWVE3i_eGdfpPa5tvYHsWrTE1NzVjdHkh25mujaSguBOS5-Dswd0WROY5fBTqqRpGlhE1lpm60ZeTPUVuiPyZvEYZjqGb8wwjOZVGyFB5ioRkac1NhaUcJ5n4EnDGKgl1CyRuvxk2D-psonnKfSqioh8aPF1Rdb_h-L59X_xmtzpHuzt6t3t3s4Lcpch_DFBZrZGOrPJPLwES25mXzXTJybHNz1jfwO8iloN
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtQw0CpFIF4QN4ECRoIniNZX7OQBIaCsWgoVQlTaN9exHVhpu7vs0dJf4-uYybHVcvStj0mceOK5PeMZQp4FF5XOo05zwatUGRUwSOhSl7uYlTxWvs52_7Svdw7Uh0E22CC_urMwmFbZycRaUIeJxz3yHuhhyQpQ2KJXtWkRn7f7r6c_UuwghZHWrp1GQyJ78fQE3Lf5q91twPVzIfrvv77bSdsOA6kHS2WRGs99MCUrTAXmGw9O6jLTAai45F4CqXLPTWBRG5MZUKTMlzIyLapShlCyIOG7l8hlIwE44CUzMKv9HYygKV6053SYzHtz0JV4nk1wEEEon_SaLqxbBvzLzv07XfOPmG2tCvs3yPXWhqVvGqK7STbi-Ba50nS1PL1N4hcwPtPRsIoUI_fLI4rin1ZAcZOTdDmlmJUKlzM6xJmOh5jsPqIh_nTYz9qBBxDp8Gg6AqTDEIrnLHG-4wgXE-9HS9zhu0MOLmSt75LNMQBwn1AhPJidUqoABmDMQ6mCqorgnVPgTRUyIbxbV-vbUufYcWNk65C7zG2DCwu4sDUurE7Ii9U706bQx7mj3yK6ViOxSHd9YzL7Zluet05zEOGsCjm4fQBX6aIoJfyUqThjUSRkq0O2bSXH3J7ReUKerh4Dz2Mgx43jZFmPURqkr1EJudfQxgoSKfMMfGpYA7NGNWugrj8ZD7_XdcVzBrOaIiEvO_o6A-v_S_Hg_L94Qq4Cn9qPu_t7D8k1gdSPlTKzLbK5mC3jIzDpFuXjmncoObxoZv0NDxRc3Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-life+medium+term+follow-up+data+for+intravitreal+dexamethasone+implant+in+retinal+vein+occlusion&rft.jtitle=Scientific+reports&rft.au=Wecker%2C+Thomas&rft.au=Grundel%2C+Bastian&rft.au=Grundel%2C+Milena&rft.au=Br%C3%BCnder%2C+Marie-Christine&rft.date=2021-04-15&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-021-87467-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_021_87467_6
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon